In this online CME self-learning program:
Psoriasis, characterized by chronic inflammation of the skin and hyperproliferation and abnormal differentiation of the stratified epidermis, is one of the most common autoimmune diseases in the U.S. With a clinical presentation of red, scaly plaques on the skin that range in severity from minor, localized lesions to complete body coverage, it is also associated with inflammation of the joints and enthesial attachments and has potential of articular destruction – a complication known as psoriatic arthritis that affects up to 30-40% of those with the disease.
A recent trial suggested that the use of a follow-up visit shortly after initiating treatment may be an effective way to boost patients; use of their medication and achieve better treatment outcomes. Interventions such as selecting the right topical delivery vehicle, better drug design, formulation, or technology are some of the suggested areas of interest for the future. A good physician-patient relationship, patient education, individualized treatment plan, psychological intervention, electronic devices, and returns visits are several other ideas suggested for better treatment outcomes particularly because the superficial nature of the disease lends itself to psychosocial comorbidity including: depression, anxiety, poor self-image and lack of self-confidence is prevalent within this population. In particular, patients with moderate-to-severe psoriasis are vulnerable. They report that their disease greatly impacts their daily lives in a negative manner, and studies have found these patients to have similar or lower quality of life when compared to people with chronic conditions including but not limited to cancer, arthritis, and cancer.
This program has been designed to bring healthcare professionals’ knowledge up to date with the currently best and recommended practices in treating Psoriasis.
Faculty introduction, disclosures
Introduction content: cursory refresher and review of Psoriasis
Treatment of Psoriasis
Summary, conclusions, and best practice recap
Healthcare professionals specializing in: dermatology, internal medicine, pediatrics, and those who otherwise commonly encounter patients with psoriasis.
This program is supported by an educational grant from Promius Pharma.
Release Date: May 16, 2016 -- Expiration Date: May 16, 2018
Faculty: Gary Cole, MD
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Dr. Gary Cole, MD has no financial relationships to disclose.
Disclosures of Educational Planners: Charles Turck, PharmD has no relevent financial disclosures.
Commercial Support Disclosure: This program is supported by an educational grant from Promius Pharma.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.